This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1994 Oct;21(5):620-9.

The clinical and biological study of androgen independent prostate cancer (AI PCa)

C J Logothetis¹, N M Hoosein, J T Hsieh

Affiliations

PMID: 7524155

Review

The clinical and biological study of androgen independent prostate cancer (AI PCa)

C J Logothetis et al. Semin Oncol. 1994 Oct.

. 1994 Oct;21(5):620-9.

Authors

C J Logothetis¹, N M Hoosein, J T Hsieh

Affiliation

¹ Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.

PMID: 7524155

No abstract available

PubMed Disclaimer

Similar articles

Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A, Di Silverio F. Sciarra A, et al. Urology. 2004 Mar;63(3):523-7. doi: 10.1016/j.urology.2003.10.043. Urology. 2004. PMID: 15028450 Clinical Trial.
Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M; Chiba Prostate Study Group. Sato N, et al. Urology. 2004 Aug;64(2):341-5. doi: 10.1016/j.urology.2004.03.032. Urology. 2004. PMID: 15302491 Clinical Trial.
Prostate cancer: improving the therapeutic index.
Scher HI. Scher HI. Semin Oncol. 1994 Oct;21(5):688-93. Semin Oncol. 1994. PMID: 7524157 Review. No abstract available.
Treatment options in androgen-independent prostate cancer.
Lara PN Jr, Meyers FJ. Lara PN Jr, et al. Cancer Invest. 1999;17(2):137-44. Cancer Invest. 1999. PMID: 10071598 Review.
Expression and role of Foxa proteins in prostate cancer.
Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ. Mirosevich J, et al. Prostate. 2006 Jul 1;66(10):1013-28. doi: 10.1002/pros.20299. Prostate. 2006. PMID: 16001449

See all similar articles

Cited by

[Chemotherapy of hormone refractory prostate carcinoma].
Wirth MP, Nippgen J. Wirth MP, et al. Urologe A. 2003 Nov;42(11):1453-60. doi: 10.1007/s00120-003-0452-y. Urologe A. 2003. PMID: 14624343 Review. German.
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.
Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Holzbeierlein J, et al. Am J Pathol. 2004 Jan;164(1):217-27. doi: 10.1016/S0002-9440(10)63112-4. Am J Pathol. 2004. PMID: 14695335 Free PMC article.
An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.
Drake MJ, Robson W, Mehta P, Schofield I, Neal DE, Leung HY. Drake MJ, et al. Br J Cancer. 2003 Mar 24;88(6):822-7. doi: 10.1038/sj.bjc.6600817. Br J Cancer. 2003. PMID: 12644816 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information